PHILADELPHIA, Dec. 16, 2010 /PRNewswire/ -- ERT (Nasdaq: ERES),
a global provider of technology and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
launch of its comprehensive suite of electronic patient-reported
outcome (ePRO) solutions. As the ePRO market continues to grow,
ePRO tools have increasingly become more sophisticated, with their
development reflecting the diverse needs of sponsors and
facilitating compliance by the patient. ERT now offers a broad
range of proven modalities of technology, offering the ability to
choose the best ePRO solution to suit the requirements of the
trial, ensuring its accuracy and success.
The selection of the ideal ePRO modality is reliant on multiple
factors including questionnaire complexity, length, site location,
patient population, budget and size of trial. To facilitate this
complex selection criteria, ERT offers a diverse range of
complementary ePRO tools accepted by regulatory authorities
globally for collection of reliable accurate data. ERT solutions
include the VIAPhone®, VIAPad®, VIAPen® and VIAWeb®, all of which
offer the advantages of simplicity, mobility and immediacy of use
over traditional paper based methods.
ERT's VIAPad solution has the capacity for complex diaries,
questionnaires and visual scales, alongside the ability to
streamline mid-study changes. The VIAWeb solution enables all
patients to use a standard internet browser at home or work to
securely log into their study diary or assessment and complete
necessary information. This is ideal for patients busy at work,
with little time to visit a clinical trial site. The VIAPen is a
digital pen that offers the simplicity of paper-based methods with
the dual advantage of digital data collection. Completing the suite
of solutions offered is the VIAPhone, otherwise known as an
Interactive Voice Response device. The VIAPhone enables a patient
to use a standard landline telephone or cell phone to feedback
information. For people reluctant to embrace more innovative
technologies or with reduced physical function, this provides the
perfect solution.
John Blakeley, Executive Vice
President and Chief Commercial Officer at ERT comments, "At ERT we
believe that 'one size does NOT fit all.' We believe that to ensure
an accurate and successful clinical trial, vendors must offer
technologies that are as diverse and varied as the clinical trials
themselves. With this in mind, ERT works to ensure that it offers a
comprehensive, unbiased choice of sophisticated solutions."
For further information on ERT and its technology and services
please email info@ert.com, call +1 215 972 0420 or visit
www.ert.com.
For further press information, please contact Fiona Robinson, The Scott Partnership, 1
Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA,
United Kingdom. Phone +44 1477
539539, Fax +44 1477 539540, Email ert@scottpr.co.uk
About ERT
Based in Philadelphia, PA,
eResearchTechnology, Inc. (www.ert.com) is a global provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries. The Company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical
development. It is also a leading provider of centralized
respiratory technology and services to evaluate pulmonary function
efficacy and safety in clinical development. Sponsors can
further use the Company's solutions to streamline the clinical
trials process by automating the collection, analysis, and
distribution of ePRO clinical data using multi-mode technology in
all phases of clinical development as well as selected medical
devices for the clinical trials and healthcare industries.
Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a
number of risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied from such
statements. These risks and uncertainties include, without
limitation, the Company's ability to obtain new contracts,
variability in size, scope and duration of projects, integration of
acquisitions, competitive factors, technological development,
market demand, and other factors described in the Company's filings
with the Securities and Exchange Commission. The Company undertakes
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise.
SOURCE ERT